A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.
A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.
The collapse of Rubius’s first attempt to demonstrate the worth of its red blood cell platform proves that this company should never have gone public.
Introducing Evaluate's Covid-19 daily roundup, a data-driven analysis of new Covid-19 cases in the world's top 20 economies.
The industry has a duty to develop Covid-19 antivirals and vaccines, but the nature of clinical trials means that lower-profile measures must take precedence.
A private Belgian biotech reckons Tigit is the new PD-1, a view Roche’s progress could validate.
Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.
Clinical results this year from companies including Roche, Biogen and Sanofi should show whether new drug classes can arrest the development of Parkinson’s disease.
Tirzepatide’s clinical programme is set to double in size when a huge head-to-head outcome study gets under way. Costs will balloon too.